Authors
Latest:
Co-Clinical Trial of Olaparib and Temozolomide in SCLC PDX ModelsBenjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.
Latest:
Immunotherapy Advances Lung Cancer Treatment LandscapeBenjamin Levy, MD, discusses how the role of immunotherapy has evolved in the treatment landscape of lung cancer and where he sees this research headed in the future.
Latest:
The Global Unmet Need in Breast Cancer CareBenjamin O. Anderson, MD, Seattle Cancer Care Alliance, discusses the current global unmet need for the treatment of patients with breast cancer.
Latest:
Targeted Therapies Show Activity in ROS1 Fusion-Positive Lung CancerBenjamin P. Levy, MD, discusses biomarkers that have led to the development therapies with high response rates in lung cancer.
Latest:
Dr. Benjamin Smith on Complication Burdens in Different Local Treatments for Breast Cancer​Benjamin Smith, MD, discusses a recent study looking at local treatments in breast cancer and the complication burdens associated with them. Smith says that any complications arising in patients with breast cancer within 2 years are strongly associated with their treatments.
Latest:
Targeted Therapies Showing Promise in Colorectal CancerBenjamin Weinberg, MD, discusses novel agents that may impact the treatment landscape for colorectal cancer once made available in the community setting.
Latest:
Sotorasib Shows Early Activity in Advanced Non–Small Cell Lung CancerIn patients with non–small cell lung cancer harboring a KRAS G12C mutation, an aberration without any FDA approved treatment options, a study showed that the investigation agent, sotorasib achieved encouraging antitumor activity.
Latest:
Obesity as a Risk Factor for Inflammatory Breast CancerBeth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, discusses obesity as a risk factor for inflammatory breast cancer.
Latest:
Similar HRQOL With Gilteritinib vs Placebo in FLT3-ITD+ AML Post-HCTBetty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.
Latest:
Challenges Remain to be Addressed With CAR T-Cell Therapy in DLBCLBianca D. Santomasso, MD, PhD, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma with CAR T-cell therapy.
Latest:
<em>RICTOR</em> Amplification in Lung CancerBilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.
Latest:
New Collaboration Forms for Immunotherapy Regimens in Hematologic MalignanciesMedImmune Limited, a subsidiary of AstraZeneca PLC, and Celgene International II Sà rl, a subsidiary of Celgene Corporation, have formed a strategic collaboration for the development and commercialization of AstraZeneca’s anti-programmed cell death-ligand 1 (PD-L1) agent MEDI4736.
Latest:
Patient Adherence, a Challenge of Oral ChemotherapyAdvances in oral chemotherapy are radically changing the way doctors, pharmacists, and their patients manage cancer, yet oral chemotherapy requires the patients themselves to correctly administer the drug, causing issues in patient adherence.<br />
Latest:
Exploring the Role of Genomic Testing in Urothelial CancerBishoy M. Faltas, MD, discusses the current use of genomic testing to guide urothelial cancer treatment.
Latest:
Tumor Tissue Analysis Provides Insight Into Tumor HeterogeneityBishoy M. Faltas, MD, discusses the significance of studying the response of tumor tissue to mutation-targeted agents in urothelial cancer.
Latest:
Gamble Discusses Exciting Topics at the Upcoming 2018 Community Oncology ConferenceRobert "Bo" Gamble, director of Strategic Practice Initiatives, Community Oncology Alliance (COA), discusses some of the exciting topics that will be covered during the upcoming 2018 Community Oncology Conference.
Latest:
The Side Effects of Lung Cancer TreatmentBonnie Addario, a lung cancer survivor, discusses toxicities involved during lung cancer treatment.
Latest:
Chemotherapy Safe After Radium-223 for Men With mCRPCThe explosion of new drugs for the treatment of castration-resistant prostate cancer (CRPC) is a welcome advance, but raises questions about how best to sequence these drugs with standard docetaxel chemotherapy.
Latest:
Microwave Ablation for the Treatment of Liver CancerBoris Kuvshinoff II, MD, MBA, associate professor, Division of Gastrointestinal/Endocrine Surgery, Department of Surgical Oncology, director, Liver and Pancreas Tumor Center, Roswell Park Cancer Institute, discusses microwave ablation therapy for the treatment of liver cancer.
Latest:
Ibrutinib in the Management of B-cell MalignanciesWhile ibrutinib is a relatively new option in the treatment of B-cell NHL, it has convincing antitumor activity as a single agent in a wide variety of B-cell lymphoma subtypes and is a viable therapeutic option for patients.
Latest:
Treating Patients With Indolent Lymphomas in the Relapsed SettingBrad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.
Latest:
Immunotherapy Combinations Improve Survival in Advanced Renal Cell CarcinomaBradley McGregor, MD, discusses the current treatment landscape for patients with advanced or metastatic renal cell carcinoma, which has significantly evolved over the last few years.
Latest:
Ibrutnib in Older Patients With Mantle Cell LymphomaBrad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.
Latest:
KEYNOTE-826: Knowledge Gained for Cervivcal Cancer TreatmentBradley J. Monk, MD, FACS, FACOG, explains the implications of the phase 3 KEYNOTE-826 clinical trial.
Latest:
Behind KEYNOTE-826 in Persistent, Recurrent, or Metastatic Cervical CancerBradley J. Monk, MD, FACS, FACOG, discusses the rationale behind the KEYNOTE-826 study.
Latest:
Monk on KEYNOTE-A18 Data of Pembro/Chemoradiotherapy in Cervical CancerBradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Latest:
McGregor Highlights Excitement and Future Directions Across GU CancersBradley McGregor, MD, discusses how ongoing trials hold the key for further breakthroughs in genitourinary cancer treatment.
